



Study	I^2	1	Odds Ratio (95% Crl)			
Afatinib_Cetuximab vs Afatinib						
29			2.3 (0.51, 11.)			
Pooled (pair-wise)			2.3 (0.20, 28.)			
Indirect (back-calculated)			NA			
Pooled (network)		- •	2.3 (0.24, 24.)			
Chemotherapy vs Afatini	ib					
50			0.79 (0.18, 3.5)			
57		<	→ 5.2e+12 (4.0e-05, 6.7e+29)			
Pooled (pair-wise)	64.7%	- •	1.5 (0.19, 14.)			
Indirect (back-calculated)			0.89 (0.21, 3.8)			
Pooled (network)	13.4%	- -	1.1 (0.32, 3.6)			
Erlotinib vs Afatinib						
38			0.81 (0.39, 1.7)			
Pooled (pair-wise)			0.81 (0.10, 6.5)			
Indirect (back-calculated)		⊙.	0.59 (0.15, 2.4)			
Pooled (network)	0.0%		0.65 (0.21, 2.1)			
Gefitinib vs Afatinib						
48			0.64 (0.21, 1.9)			
Pooled (pair-wise)			0.64 (0.068, 5.8)			
Indirect (back-calculated)			0.58 (0.13, 2.6)			
Pooled (network)	0.0%		0.60 (0.17, 2.1)			
Placebo vs Afatinib						
54			0.20 (0.039, 1.1)			
Pooled (pair-wise)			0.21 (0.014, 2.4)			
Indirect (back-calculated)		⊙	0.70 (0.17, 2.9)			
Pooled (network)	28.4%		0.53 (0.15, 1.8)			
		0.02	50			
		0.02				





Study	I^2			Odds Ratio (95% CrI)			
Erlotinib_chemotherapy vs Chemotherapy							
71 Pooled (pair–wise) Indirect (back–calculated) Pooled (network)	0.0%	←	• • • • • • • • • • • • • • • • • • •	0.38 (0.020, 7.3) 0.38 (0.011, 13.) 0.56 (0.070, 4.4) 0.50 (0.082, 2.9)			
Gefitinib vs Chemothera	ру						
73 75 76 77		← ←		→ 5.7e-21 (4.5e-51, 7.2e+09) → 4.8e-21 (4.1e-51, 5.5e+09) 0.98 (0.11, 9.0) → 4.2e-21 (2.3e-51, 7.9e+09)			
Pooled (pair–wise) Indirect (back–calculated) Pooled (network)	54.0% 27.6%	<u> </u>	······································	0.23 (0.017, 1.8) 0.76 (0.20, 2.8) 0.57 (0.18, 1.7)			
Osimertinib vs Chemothe	erapy						
42 Pooled (pair–wise) Indirect (back–calculated) Pooled (network)	0.0%	-		0.70 (0.25, 1.9) 0.70 (0.077, 6.3) 0.67 (0.11, 4.2) 0.68 (0.16, 2.7)			
Erlotinib vs Dacomitinib							
45 59 Pooled (pair–wise) Indirect (back–calculated) Pooled (network)	0.0%	0.02	1	2.3 (0.34, 16.) 0.87 (0.30, 2.5) 1.3 (0.24, 7.0) 1.1 (0.22, 5.7) 1.2 (0.37, 3.9)			











Study	I^2				Odds Ratio (95% Crl)	
Lazertinib vs Gefitinib						
r17			_		1.2 (0.40, 3.4)	
Pooled (pair-wise)					1.2 (0.13, 11.)	
Indirect (back-calculated)				.⊙	1.9 (0.18, 20.)	
Pooled (network)	0.0%			•	1.5 (0.29, 7.4)	
Placebo vs Gefitinib						
64					0.80 (0.19, 3.3)	
r5		\leftarrow		\longrightarrow	3.6e-21 (6.6e-51, 2.0e+09)	
Pooled (pair-wise)	61.6%		-		0.41 (0.043, 2.9)	
Indirect (back-calculated)			6)	1.2 (0.32, 4.4)	
Pooled (network)	0.9%				0.88 (0.29, 2.6)	
antiangio vs Gefitinib						
3				$\longrightarrow\!$	28. (2.0, 4.0e+02)	
Pooled (pair-wise)				$\xrightarrow{ \bullet }$	23. (1.5, 9.2e+02)	
Indirect (back-calculated)				······O······	7.6 (1.4, 42.)	
Pooled (network)	0.0%			$\stackrel{\bullet}{\longrightarrow}$	9.8 (2.4, 50.)	
Osimertinib vs Lazertinil	b					
r1					0.68 (0.21, 2.3)	
Pooled (pair-wise)		_	-		0.68 (0.071, 6.7)	
Indirect (back-calculated)			ф		0.97 (0.11, 8.4)	
Pooled (network)	0.0%				0.82 (0.17, 4.0)	
Osimertinib_chemotherapy vs Osimertinib						
70		\leftarrow		\longrightarrow	8.0e+12 (2.1e-08, 3.0e+33)	
r16			+	$\overline{}$	2.8 (0.80, 9.7)	
Pooled (pair-wise)	35.4%		-		3.6 (0.47, 36.)	
Indirect (back-calculated)					NA	
Pooled (network)	35.2%		-	 -,	3.6 (0.53, 30.)	
		0.02	1	5()	

